OnCo
drugsProductPhase 3

Mezigdomide

Mezigdomide is the most potent oral cereblon modulator, producing responses in about 40% of triple-class-refractory myeloma with dexamethasone alone.

CC-92480-MM-001: ORR 41% (MeziDex) in heavily pretreated disease including 30% with extramedullary disease. SUCCESSOR-1 (Mezi-Vd vs Pom-Vd) and SUCCESSOR-2 (Mezi-Kd vs Kd) phase 3 trials ongoing.

Loading structure…
|
Mezigdomide
PubChem
Modality
CELMoD (cereblon E3 ligase modulator)
Mechanism
High-affinity cereblon modulator; rapid, deep Ikaros/Aiolos degradation with strong T-cell co-stimulation.
Brand / code
CC-92480

Trials

top
ClinicalTrials.gov · phase 2/3
refreshed 2026-09-09
13 studies7 recruiting11 Phase 22 Phase 3
Search “Mezigdomide” on ClinicalTrials.gov →
Counts are from a name search and may include unrelated studies; up to 100 studies are summarised.

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
Mezigdomide
intervention: Mezigdomide
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Latest papers

top
Literature trend9 papers in the last 12 months+50% vs prior 12How this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this drug: (TITLE:"Mezigdomide" OR ABSTRACT:"Mezigdomide" OR TITLE:"CC-92480" OR ABSTRACT:"CC-92480") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mezigdomide, not a curated reading list.

Connected

4top